Search results
May 13, 2024 · Hummingbird Bioscience is leading a bold new way of engineering biotherapeutics that can define the future of precision medicine. Building on our deep experience in biologics discovery and development, coupled with our proprietary linker-payload technologies, we are developing a pipeline of next-generation antibody-based therapeutics ...
We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.
Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model...
Sep 24, 2022 · SINGAPORE - Singapore-based biomedical start-up Hummingbird Bioscience, which specialises in developing antibodies for cancer treatment, on Friday launched a new facility to expand its...
Hummingbird. Hummingbird has come a long way since you started in 2015. The team has now grown into 150 strong, responsible for the full range of drug discovery and development activities. You are now a leading start-up in the field of precision biotherapeutics for cancer and autoimmune diseases.
Sep 23, 2022 · The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery...
Sep 23, 2022 · The latest addition to Singapore's growing biotech scene is Hummingbird Bioscience - a 40,000 sq ft, multimillion-dollar facility that looks into treatments for hard-to-treat diseases like...
Oct 23, 2023 · Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced presentation of...
Hummingbird Bioscience, a Singapore founded biotech company focused on the discovery and development of novel antibody-based therapeutics, today announced the successful completion of an extended Series A financing round.
We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.
